BioRegenx, Inc.
BRGX
$0.0115
-$0.0005-4.17%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.31M | 2.34M | 2.56M | 2.76M | 2.89M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.31M | 2.34M | 2.56M | 2.76M | 2.89M |
| Cost of Revenue | 625.50K | 681.80K | 844.00K | 952.90K | 953.70K |
| Gross Profit | 1.68M | 1.66M | 1.71M | 1.80M | 1.93M |
| SG&A Expenses | 3.66M | 6.52M | 5.25M | 8.04M | 8.24M |
| Depreciation & Amortization | 1.69M | 1.69M | 1.12M | 562.10K | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.97M | 8.89M | 7.22M | 9.56M | 9.19M |
| Operating Income | -3.66M | -6.55M | -4.66M | -6.80M | -6.30M |
| Income Before Tax | -20.17M | -23.05M | -4.91M | -7.03M | -6.52M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.17 | -23.05 | -4.91 | -7.03 | -6.52 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.17M | -23.05M | -4.91M | -7.03M | -6.52M |
| EBIT | -3.66M | -6.55M | -4.66M | -6.80M | -6.30M |
| EBITDA | -1.63M | -4.03M | -2.71M | -5.43M | -5.80M |
| EPS Basic | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | -0.01 | 0.00 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | -0.01 | 0.00 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 3.84B | 3.65B | 3.38B | 3.04B | 2.85B |
| Average Diluted Shares Outstanding | 3.84B | 3.65B | 3.38B | 3.04B | 2.85B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |